{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:05:59Z","timestamp":1784700359677,"version":"3.55.0"},"reference-count":61,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The first Association of British Neurologists (ABN) UK multiple sclerosis (MS) pregnancy guidelines were published in 2019. Along with new disease-modifying treatments, significant new data have since become available, resulting in label changes and recognition of class effects. Alongside this, there has been increasing recognition of the importance of family planning considerations in treatment paradigms in MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We set out to update the ABN UK MS Pregnancy guidance with a systematic literature search, with updated guidance informed by multidisciplinary input from across neurology, obstetric medicine, pharmacy and specialist nurses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Guidance:<\/jats:title>\n                    <jats:p>Key updates include consideration of disease-modifying therapy mechanism and durability of action when discussing treatment approaches around pregnancy, alongside considering the impact of treatment withdrawal on relapses during pregnancy and in the postpartum period. Monoclonal antibody transfer into breast milk is generally accepted to be low, and so treatment during lactation can be considered. Active discussion around vaccination strategies during pregnancy and of the neonate is required, with vaccines generally considered safe. With active treatment strategies that take these factors into account, women can be reassured regarding disease control during pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Data sources remain limited, and further dedicated real-world studies that capture the full range of outcomes required to inform risk\u2013benefit discussions are needed. These require collaboration and infrastructure to support the delivery of high-quality care to all women with MS considering pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585261454551","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:28:02Z","timestamp":1783099682000},"page":"885-896","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["UK consensus on pregnancy in multiple sclerosis: An update to \u2018Association of British Neurologists\u2019 guidance"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8760-4820","authenticated-orcid":false,"given":"Ger","family":"Mullan","sequence":"first","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-5046","authenticated-orcid":false,"given":"Helen L","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Neurology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Faculty of Health and Life Sciences, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Blackall","sequence":"additional","affiliation":[{"name":"Department of Neurology, Buckinghamshire NHS Trust Hospitals, Buckinghamshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7827-9933","authenticated-orcid":false,"given":"Denisse","family":"Bongol","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Bonham","sequence":"additional","affiliation":[{"name":"Department of Neurology, Forth Valley Royal Hospital, Larbert, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brex","sequence":"additional","affiliation":[{"name":"Department of Neurology, King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Hoyle","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Neurology, Forth Valley Royal Hospital, Larbert, UK; Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Nelson-Piercy","sequence":"additional","affiliation":[{"name":"Department of Obstetric Medicine, Guy\u2019s &amp; St Thomas\u2019 Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-0200","authenticated-orcid":false,"given":"Owen R","family":"Pearson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Swansea Bay University Health Board, Port Talbot, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rog","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, UK; University of Salford, Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paarul","family":"Prinja","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-585X","authenticated-orcid":false,"given":"Ruth","family":"Dobson","sequence":"additional","affiliation":[{"name":"Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University, London, UK; Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2018-002060"},{"key":"e_1_3_2_3_2","volume-title":"Treatment algorithm for multiple sclerosis disease-modifying therapies","author":"NHS England","year":"2023","unstructured":"NHS England. Treatment algorithm for multiple sclerosis disease-modifying therapies. London: NHS England, 2023."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004228"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004459"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06838-1"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012084"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.2550"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201027"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200106"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200371"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221148094"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241293363"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12126"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000959"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331525"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/11531280-000000000-00000"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/0890334417706359"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103963"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517717806"},{"key":"e_1_3_2_21_2","unstructured":"The Royal College of Radiologists. RCR and SoR statement on patients who are breastfeeding who require a CT or MRI with contrast https:\/\/www.rcr.ac.uk\/news-policy\/latest-updates\/rcr-and-sor-statement-on-patients-who-are-breastfeeding-who-require-a-ct-or-mri-with-contrast\/ (2022 accessed 14 July 2025)."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103700"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104844"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101137"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44750"},{"key":"e_1_3_2_26_2","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks","volume":"90","author":"Portaccio E","year":"2018","unstructured":"Portaccio E, Moiola L, Martinelli V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology 2018; 90: e832\u2013e839.","journal-title":"Neurology"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332804"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0674-4"},{"key":"e_1_3_2_29_2","first-page":"392","article-title":"Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)","volume":"95","author":"Toorop AA","year":"2024","unstructured":"Toorop AA, van Lierop ZYGJ, Gelissen LMY, et al. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS). J Neurol Neurosurg Psychiat 2024; 95: 392\u2013400.","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203335"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2026.107086"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0890334414566237"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000769"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517728813"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200349"},{"key":"e_1_3_2_36_2","unstructured":"Hellwig K Bove R Dobson R et al. B cell levels and placental transfer in infants potentially exposed to ocrelizumab during pregnancy: Analysis of the Phase IV MINORE study https:\/\/medically.roche.com\/global\/en\/neuroscience\/ectrims-2024\/medical-material\/ECTRIMS-2024-poster-hellwig-b-cell-levels-and-placental-transfer-in-infants-pdf.html (2024 accessed 5 May 2025)."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51893"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200264"},{"key":"e_1_3_2_39_2","article-title":"B-cell levels and breastmilk transfer in infants of lactating women with multiple sclerosis treated with ocrelizumab: Primary results of the prospective, multicentre, open-label, phase IV study SOPRANINO","volume":"31","author":"Bove R","year":"2025","unstructured":"Bove R, Oreja-Guevara C, Hellwig K, et al. B-cell levels and breastmilk transfer in infants of lactating women with multiple sclerosis treated with ocrelizumab: Primary results of the prospective, multicentre, open-label, phase IV study SOPRANINO. Abstract 0102, Mult Scler 2025; 31: 3 supplement.","journal-title":"Mult Scler"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241274600"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231220232"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1393752"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420968414"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103951"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519843055"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103529"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520929628"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104184"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae011"},{"key":"e_1_3_2_50_2","unstructured":"Novartis. Gilenya 0.25 mg hard capsules https:\/\/www.medicines.org.uk\/emc\/product\/4545\/smpc (2025 accessed 31 August 2025)."},{"key":"e_1_3_2_51_2","unstructured":"Novartis. Mayzent 0.25 mg film-coated tablets https:\/\/www.medicines.org.uk\/emc\/product\/11019\/smpc (2025 accessed 31 August 2025)."},{"key":"e_1_3_2_52_2","unstructured":"Bristol Myers Squibb Pharmaceuticals. Zeposia 0.23 mg hard capsules https:\/\/www.medicines.org.uk\/emc\/product\/11906\/smpc (2025 accessed 31 August 2025)."},{"key":"e_1_3_2_53_2","unstructured":"Laboratoires Juvise Pharmaceuticals. Ponvory 2 3 4 5 6 7 8 9 10 mg film-coated tablets https:\/\/www.medicines.org.uk\/emc\/product\/100488\/smpc (2025 accessed 31 August 2025)."},{"key":"e_1_3_2_54_2","first-page":"334629","article-title":"Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning","volume":"96","author":"Jeantin L","year":"2024","unstructured":"Jeantin L, Bensa-Koscher C, Deschamps R, et al. Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning. J Neurol Neurosurg Psychiat 2024; 96: 334629.","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200110"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231183547"},{"key":"e_1_3_2_57_2","unstructured":"LEMTRADA 12 mg concentrate for solution for infusion https:\/\/www.medicines.org.uk\/emc\/product\/15496\/smpc (accessed 19 October 2025)."},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00749-x"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3441"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113643"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024342"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251316474"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261454551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585261454551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261454551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:49:56Z","timestamp":1784699396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585261454551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/13524585261454551"],"URL":"https:\/\/doi.org\/10.1177\/13524585261454551","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}